CD8A and neoplasm: On the contrary, HS-1793 treatment significantly enhanced tumor-specific cytotoxic T lymphocyte responses in tumor-bearing mice by upregulating the interferon (IFN)-γ-expressing CD8+ T cell population [217,218].